|
|
||||||||||
Associate Medical Director, Abbott Laboratories, Inc., Abbott Park, IL; Clinical Assistant Professor, Department of Anesthesiology, The Chicago Medical School, Chicago, IL
Assistant Professor of Anesthesiology, Division of Critical Care and Perioperative Medicine, Vanderbilt University, Nashville, TN
Nurse Practitioner for Critical Care, Catholic Medical Center, Manchester, NH
Associate Professor, Department of Anesthesiology and Perioperative Medicine, Oregon Health Sciences University, Portland, OR
Chief Resident, Department of Anesthesiology and Perioperative Medicine, Oregon Health Sciences University
Reprints: Victor SB Jorden MD MPH, Department R440, Abbott Laboratories, 200 Abbott Park Dr., Abbott Park, IL 60046-6229, fax 847/935-7633, victor.jorden{at}abbott.com
OBJECTIVE: To report 3 cases of accidental
dexmedetomidine overdose in the perioperative setting and review the
pathophysiology of
2-agonist overdose.
CASE SUMMARIES: Three patients accidentally received overdoses of dexmedetomidine, one intraoperatively (192 µg over 20 min) and 2 postoperatively (4 and 2 rather than 0.4 and 0.2 µg/kg/h; 0.5 µg/kg/min rather than 0.5 µg/kg/h). Hemodynamic parameters remained stable for all 3 patients. The most notable sign was oversedation diagnosed either clinically or using a bispectral index monitor; Naranjo criteria suggest possible or probable association of the reactions with dexmedetomidine. In all 3 cases, oversedation resolved within one hour of drug discontinuation. There were no other sequelae, and the remainder of each patient's hospital course was unremarkable.
DISCUSSION: As of this writing, dexmedetomidine dosing in
excess of the label recommendation has been reported, but accidental
dexmedetomidine overdose in clinical practice has not been described.
Excessive levels of sedation were the only significant finding in all 3
patients. Dexmedetomidine's short redistribution half-life of 6 minutes should
lead to rapid resolution of oversedation induced by overdoses if the overall
duration of infusion is short (
8 h). While the patients reported here were
hemodynamically stable, dexmedetomidine may engender significant hemodynamic
changes either because of sympatholysis at normal doses or vasoconstriction at
higher than recommended doses. The absence of a significant hypertensive
response to high dexmedetomidine concentrations suggests that
dexmedetomidine-induced hypertension may be multifactorial, not simply related
to plasma drug concentrations.
CONCLUSIONS: Practitioners presented with dexmedetomidine overdose should be prepared to manage oversedation. While hemodynamic alterations may be seen with dexmedetomidine use, hypertension from high dexmedetomidine plasma concentrations is not a consistent response. Practitioners using dexmedetomidine should carefully note that dosing for this agent is described by the manufacturer in µg/kg/h, not µg/kg/min.
Key Words: dexmedetomidine, overdose
Published Online, March 23, 2004. www.theannals.com, DOI 10.1345/aph.1D376
This article has been cited by other articles:
![]() |
M. P. Hutchens and P. Thorborg Dexmedetomidine Sedation (and Cardiac Perforation, Pericardial Tamponade, Cardiac Arrest, and Cardiopulmonary Resuscitation) Leading to Refractory Cardiogenic Shock Anesth. Analg., January 1, 2009; 108(1): 379 - 380. [Full Text] [PDF] |
||||
![]() |
A. T Gerlach and J. F Dasta Dexmedetomidine: An Updated Review Ann. Pharmacother., February 1, 2007; 41(2): 245 - 252. [Abstract] [Full Text] [PDF] |
||||